FDA Approval of Dynavax's (DVAX) Groundbreaking Hep-B Vacccine Could Double Its Value - Cramer
Tweet
Share
E-mailGet Alerts DVAX Hot Sheet
Price: $15.50 --0%
Rating Summary:
9 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Dynavax Technologies (Nasdaq: DVAX) shares are trading stronger Monday following a positive mention by stock guru Jim Cramer late last Friday.
Cramer noted that Dyunavax has a late-stage hepatitis-B drug which is very promising for the company. The drug has a success rate of 91 percent after just two shots, versus 81 percent success rate after three shots for the current market-leading hep-B vaccine.
Despite the drug being groundbreaking, Cramer noted that the FDA recently approved a similar vaccine for cervical cancer.
Though Cramer is bullish on the potential, he said investors should do their homework and exercise caution. Should FDA approval be granted, Dynavax shares could double...or they could slump over 50 percent on an adverse ruling. No news is expected for the next six weeks.
With a current market value of $800 million and the market for hep-B vaccines at about $1.5 billion, sales of Dynavax's proposed vaccine getting about half the market share by 2018 could double the value of the company. Shares are up about 4 percent Monday morning.
Cramer noted that Dyunavax has a late-stage hepatitis-B drug which is very promising for the company. The drug has a success rate of 91 percent after just two shots, versus 81 percent success rate after three shots for the current market-leading hep-B vaccine.
Despite the drug being groundbreaking, Cramer noted that the FDA recently approved a similar vaccine for cervical cancer.
Though Cramer is bullish on the potential, he said investors should do their homework and exercise caution. Should FDA approval be granted, Dynavax shares could double...or they could slump over 50 percent on an adverse ruling. No news is expected for the next six weeks.
With a current market value of $800 million and the market for hep-B vaccines at about $1.5 billion, sales of Dynavax's proposed vaccine getting about half the market share by 2018 could double the value of the company. Shares are up about 4 percent Monday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Idex Corp. (IEX) Reiterated at Buy by Stifel
Create E-mail Alert Related Categories
Analyst Comments, Insiders' BlogRelated Entities
Jim CramerSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
